Drug Delivery and Translational Research

CRS members receive a free online subscription   

Drug Delivery and Translational Research is a journal published by CRS, providing a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. The journal is published 6 times a year and will be available online to CRS members as part of their annual dues.

Access DDTR Online                Editor-in-Chief Article                Enjoy Articles of DDTR

We welcome research focused on the following areas of translational drug delivery research:

  • Designing and developing novel drug delivery systems, with a focus on their application to disease conditions
  • Preclinical and clinical data related to drug delivery systems
  • Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
  • Short-term and long-term biocompatibility of drug delivery systems, host response
  • Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering
  • Image-guided drug therapy
  • Nanomedicine
  • Devices for drug delivery and drug/device combination products

In addition to original full-length papers, communications, and reviews, the journal will also include editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of CRS.

DDTR Research Editors          DDTR Editorial Board

What's New? 

February 2023 Issue


Best Papers of the February 2023 Issue of DDTR (listed by corresponding authors):

Best Paper

Summary: Thymoquinone (TQ) is a quinone-based phenolic compound with antioxidant and anti-
inflammatory activities, but its therapeutic utility has been underexplored due to inadequate
biological stability, short half-life, low hydrophilicity, and poor systemic bioavailability.
Tamanu oil-stabilized nanostructured lipid carriers (TQ-NLCs) enriched with TQ were
prepared and optimized using Box-Behnken design with the size of 153.9 ± 0.5 nm and
surface charge of -30.7 mV. The encapsulation efficiency and drug loading density were
found to be 84.6 ± 0.5 % and 14.8 ± 0.5 %, respectively. The TQ-NLCs assayed for skin
permeation for transdermal delivery where TQ-NLC provided roughly 15 times greater
permeation compared to aqueous solution of TQ. Tamanu oil displayed a synergistic anti-
inflammatory potential with TQ in comparison to TQ alone in carrageenan-induced paw
oedema model and Freund's adjuvant-induced arthritic model. The arthritic and X-ray scores
significantly reduced in TQ-NLC-treated and standard formulation-treated groups. Moreover,
serum pro-inflammatory TNF-α and IL-6 levels were significantly reduced in TQ-NLC-treated
group compared to the arthritic control group.

Best Papers of the December 2022 Issue of DDTR (listed by corresponding authors): 

Summary: We introduce a novel antiviral nano-drug called SNAT (Smart Nano-Enabled
Antiviral Therapeutic) composed of taxoid (Tx)-decorated amino (NH 2 )-functionalized silver
nanoparticles (Tx–[NH 2 -AgNPs]). The particles are around 5 nm in diameter, positively charged
and stable for over three years at room temperature. We assessed the preclinical efficacy of
inhaled SNAT where we found that SNAP significantly reversed the body weight loss, reduced
the virus load in oral swabs, and improved lung health of hamsters infected with SARS-CoV-2.
Further, SNAT was found to be noncytotoxic and antioxidant, potentially quenching lipid
peroxidation, in human lung epithelial cells and dermal fibroblasts. Overall, our study
collectively highlights SNAT as a safe and potent antiviral platform against SARS-CoV-2
infection and potentially other respiratory viruses of epidemic and pandemic potential.

Mandip Singh: Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy

Summary: A potent therapeutic option is sorely needed for triple negative breast cancer (TNBC) due to its clinical concerns, such as poor prognosis, drug resistance, and tumor recurrence. We here explored anti-cancer potential of synthetic cannabidiol (CBD; GLP grade) as a monotherapy or a chemosensitizer for doxorubicin (DOX) in TNBC (i.e., MDA-MB-231 and MDA-MB-468) cells. In comparison to 2D cultures, CBD showed greater IC 50 values in hydrogel-based 3D cultures of MDA-MB-231 and MDA-MB-468 cells. Next-generation RNA sequencing revealed GADD45A, GADD45G, FASN, LOX, and integrin (i.e., -α5, -β5) genes to be novelly altered by CBD in MDA-MB-231 cells. CIM-16 plate-based migration assay and western blotting analysis disclosed that CBD induced anti-migratory effects in TNBC cells. Western blotting, RT-qPCR, and immunocytochemistry revealed that CBD inhibited autophagy of TNBC cells. CBD pre-treatment increased DOX sensitivity in TNBC cells. CBD pre-treatment accompanied by DOX treatment decreased LOX, integrin-α5, and increased caspase 9 respectively in MDA-MB-468 cells.

Maria Jose Alonso: Quantification of the actual composition of polymeric nanocapsules: a quality control analysis

Summary: The exact compositions of nanocarriers are rarely described in the literature. However, this information is critical for understanding and/or predicting the biological behaviors of the nanocarriers. This paper describes for the first time the exact composition of polymeric nanocapsules using liquid chromatography-mass spectrometry methodology and the results shows that actual composition is significantly different from the theoretical one. While the work focuses on polymeric nanocapsules, this methodology can be broadly applicable to other nanosystems and would be crucial for understating protein corona formation and targeting capability of functionalized nanocarriers.


Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

This newly published DDTR “Perspective” article discusses the roles of drug delivery technologies in developing safe and efficacious vaccines. We thank Drs. Robert Langer, Pieter Cullis, Olivia Merkel and Mark Prausnitz for sharing their perspectives and insights on this important topic.

DDTR Videos

Editor-in-Chief María José Alonso, PhD talks about DDTR, an official journal of the CRS.

Prof. Ben Boyd, President of the CRS and Editor of DDTR, talks about his experience with the DDTR, an official journal of the CRS.

Inspirational Note


Inspirational Note by Wim H. De Jong, Robert E. Geertsma & Gerrit Borchard: Regulatory safety evaluation of nanomedical products: key issues to refine

This newly released Inspirational Note discusses critical considerations for the clinical implementation of nanomedicine.

Inspirational note by Martin J. Whitaker, Hiep Huatan and Richard J. Ross

Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm

The newly published Inspirational Note features innovative drug delivery technology that replicates the physiological cortisol diurnal rhythm for chronotherapy.


Inspirational note by James Goodson and Dr. Paul Rota

Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination

In this inspirational note, James Goodson and Dr. Paul Rota provide insightful and timely perspective and discussion regarding the importance of vaccine delivery technology and multidisciplinary efforts to achieve global vaccination and ultimately well-being.

Dr. Andrew L. Lewis

 Inspirational note by Dr. Andrew L. Lewis

Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery

In this Inspirational Note, Dr. Andrew Lewis and coauthors feature an amazing and innovative discovery that is changing the paradigm of oral peptide delivery.


DDTR 2020 Best Paper

2020 DDTR Best Paper of the Year: Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B.



2019 DDTR Best Paper of the Year: Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms


2019 CRS Nanomedicine and Nanoscale Delivery (NND) Best Paper of the Year: Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses


2019 DDTR CRS Oral Drug Delivery Focus Group Paper of the Year Award: Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer

Read DDTR's First Inspirational Note: Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men

ISSN: 2190-3948

Maria José Alonso, PhD - University of Santiago de Complotela, Spain